Blog
RSS FeedPosted by Michael Wonder on 08 Apr 2020
Pharmaceutical profits and public health are not incompatible
8 April 2020 - We need the capital and creativity of the private sector to take on the coronavirus. ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 26 Mar 2020
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
26 March 2020 - Collaboration to address product development and scale up challenges posed by current pandemic. ...
Posted by Michael Wonder on 20 Mar 2020
Coronavirus vindicates capitalism
19 March 2020 - Drug companies will save lives, even as Bernie Sanders is denouncing them. ...
Posted by Michael Wonder on 17 Mar 2020
Generic ‘identity’ gets lost when companies juggle both generic and brand drugs
17 March 2020 - We think we know generic drug companies. They challenge patents held by brand firms. They litigate ...
Posted by Michael Wonder on 03 Mar 2020
The coronavirus could help pharma reset its reputation in Washington
3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...
Posted by Michael Wonder on 03 Mar 2020
'Get it done. We need it': Trump's coronavirus message to big pharma
3 March 2020 - President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with ...
Posted by Michael Wonder on 06 Jan 2020
Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
3 January 2020 - A federal judge dealt the pharmaceutical industry a setback by declining to block a new California ...
Posted by Michael Wonder on 19 Dec 2019
North America trade pact deals rare setback to big pharma
19 December 2019 - A revamped North American trade deal nearing passage in Congress gives both the White House and ...
Posted by Michael Wonder on 10 Dec 2019
Do large pharma companies provide drug development innovation? Our analysis says no.
10 December 2019 - Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. ...
Posted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 26 Nov 2019
Teva, drug makers in talks with U.S. to end generics probes
26 November 2019 - Deferred prosecution agreements among resolutions discussed. ...
Posted by Michael Wonder on 22 Nov 2019
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
21 November 2019 - International reference pricing provisions in plan would decimate development of innovative medicines by nearly 90%. ...
Posted by Michael Wonder on 26 Oct 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
23 October 2019 - This study determined the extent to which late stage development of new drugs relies on support from ...
Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads. ...